JP7089480B2 - Ｎａｄ＋を増大させる前駆体としてのニコチン酸リボシド又はニコチンアミドリボシド誘導体、及びその還元誘導体の使用 - Google Patents

Ｎａｄ＋を増大させる前駆体としてのニコチン酸リボシド又はニコチンアミドリボシド誘導体、及びその還元誘導体の使用 Download PDF

Info

Publication number
JP7089480B2
JP7089480B2 JP2018554765A JP2018554765A JP7089480B2 JP 7089480 B2 JP7089480 B2 JP 7089480B2 JP 2018554765 A JP2018554765 A JP 2018554765A JP 2018554765 A JP2018554765 A JP 2018554765A JP 7089480 B2 JP7089480 B2 JP 7089480B2
Authority
JP
Japan
Prior art keywords
acid
nad
derivatives
derivative
mitochondrial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018554765A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019514874A (ja
JP2019514874A5 (enExample
Inventor
デリンジャー，ライアン
ローンマス，トロイ
モリス，マーク
エリクソン，アロン
カシアー，ハディ
ミゴード，マリー，イー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chromadex Inc
Original Assignee
Chromadex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chromadex Inc filed Critical Chromadex Inc
Publication of JP2019514874A publication Critical patent/JP2019514874A/ja
Publication of JP2019514874A5 publication Critical patent/JP2019514874A5/ja
Priority to JP2021117648A priority Critical patent/JP2021176871A/ja
Application granted granted Critical
Publication of JP7089480B2 publication Critical patent/JP7089480B2/ja
Priority to JP2022167877A priority patent/JP7493007B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)
JP2018554765A 2016-04-20 2017-04-20 Ｎａｄ＋を増大させる前駆体としてのニコチン酸リボシド又はニコチンアミドリボシド誘導体、及びその還元誘導体の使用 Active JP7089480B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021117648A JP2021176871A (ja) 2016-04-20 2021-07-16 Ｎａｄ＋を増大させる前駆体としてのニコチン酸リボシド又はニコチンアミドリボシド誘導体、及びその還元誘導体の使用
JP2022167877A JP7493007B2 (ja) 2016-04-20 2022-10-19 Ｎａｄ＋を増大させる前駆体としてのニコチン酸リボシド又はニコチンアミドリボシド誘導体、及びその還元誘導体の使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662325264P 2016-04-20 2016-04-20
US62/325,264 2016-04-20
PCT/US2017/028673 WO2017184885A1 (en) 2016-04-20 2017-04-20 Use of nicotinic acid riboside or nicotinamide ribosite derivatives, and reduced derivatives thereof, as nad+increasing precursors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021117648A Division JP2021176871A (ja) 2016-04-20 2021-07-16 Ｎａｄ＋を増大させる前駆体としてのニコチン酸リボシド又はニコチンアミドリボシド誘導体、及びその還元誘導体の使用

Publications (3)

Publication Number Publication Date
JP2019514874A JP2019514874A (ja) 2019-06-06
JP2019514874A5 JP2019514874A5 (enExample) 2020-05-28
JP7089480B2 true JP7089480B2 (ja) 2022-06-22

Family

ID=60088650

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018554765A Active JP7089480B2 (ja) 2016-04-20 2017-04-20 Ｎａｄ＋を増大させる前駆体としてのニコチン酸リボシド又はニコチンアミドリボシド誘導体、及びその還元誘導体の使用
JP2021117648A Pending JP2021176871A (ja) 2016-04-20 2021-07-16 Ｎａｄ＋を増大させる前駆体としてのニコチン酸リボシド又はニコチンアミドリボシド誘導体、及びその還元誘導体の使用
JP2022167877A Active JP7493007B2 (ja) 2016-04-20 2022-10-19 Ｎａｄ＋を増大させる前駆体としてのニコチン酸リボシド又はニコチンアミドリボシド誘導体、及びその還元誘導体の使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021117648A Pending JP2021176871A (ja) 2016-04-20 2021-07-16 Ｎａｄ＋を増大させる前駆体としてのニコチン酸リボシド又はニコチンアミドリボシド誘導体、及びその還元誘導体の使用
JP2022167877A Active JP7493007B2 (ja) 2016-04-20 2022-10-19 Ｎａｄ＋を増大させる前駆体としてのニコチン酸リボシド又はニコチンアミドリボシド誘導体、及びその還元誘導体の使用

Country Status (13)

Country Link
US (1) US10183036B2 (enExample)
EP (1) EP3445359B8 (enExample)
JP (3) JP7089480B2 (enExample)
KR (1) KR20190008246A (enExample)
CN (1) CN109640984A (enExample)
AU (2) AU2017254657A1 (enExample)
BR (1) BR112018071573A2 (enExample)
CA (1) CA3021571C (enExample)
ES (1) ES2948968T3 (enExample)
MX (1) MX393076B (enExample)
NZ (1) NZ747693A (enExample)
WO (1) WO2017184885A1 (enExample)
ZA (1) ZA201807736B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3322419B1 (en) * 2015-07-15 2025-09-03 Cornell University Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives
EA035664B1 (ru) 2015-08-05 2020-07-23 МЕТРО ИНТЕРНЭШНЛ БАЙОТЕК, ЭлЭлСи Производные никотинамидмононуклеотида и их применение для лечения заболевания или расстройства, связанного с биосинтезом над+
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
CA3045876A1 (en) 2016-11-11 2018-05-17 The Queen's University Of Belfast Scalable syntheses of nicotinoyl ribosides and reduced nic otinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof
BR112019010607B1 (pt) 2016-11-29 2023-10-31 University Of Iowa Research Foundation Uso de precursores de nad e composição compreendendo os referidos precursores
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
WO2018191771A1 (en) * 2017-04-18 2018-10-25 Victor Chang Cardiac Research Institute Detection and treatment of congenital malformations
SG11201912267SA (en) 2017-06-19 2020-01-30 Gangadhara Ganapati Nicotinamide riboside derivatives and their uses
AU2019214858B2 (en) * 2018-01-30 2023-02-02 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
JP2021525279A (ja) * 2018-05-22 2021-09-24 ジャンプスタート ファーティリティ ピーティーワイ リミテッド 抗加齢剤としてのニコチン酸リボシドのアミノ酸塩
US11833167B2 (en) 2018-12-17 2023-12-05 Mitopower Llc Nicotinyl riboside compounds and their uses
CN113727987A (zh) * 2019-02-21 2021-11-30 可劳迈戴斯有限公司 烟酰胺核苷、烟酸核苷、还原型烟酰基核苷化合物和烟酰基核苷化合物衍生物在制品的用途
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
JP7610531B2 (ja) * 2019-06-05 2025-01-08 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 腎疾患を治療又は予防するための還元型ニコチンアミドリボシド
EP3980028A1 (en) * 2019-06-05 2022-04-13 Société des Produits Nestlé S.A. Reduced nicotinamideribosides for treating/preventing skeletal muscle disease
CN113840612A (zh) * 2019-06-05 2021-12-24 雀巢产品有限公司 用于治疗/预防肝脏疾病的还原型烟酰胺核糖核苷
CN110973260A (zh) * 2019-12-11 2020-04-10 杨力 一种含有烟酰胺核糖苷的牛奶及其制备方法与应用
US20230000888A1 (en) 2019-12-19 2023-01-05 Leibniz-Institut Für Alternsforschung - Fritz-Lipmann-Institut E.V. (Fli) Nad-precursors and dietary restriction for treating age related medical conditions
WO2021180732A1 (en) * 2020-03-09 2021-09-16 Société des Produits Nestlé S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of neurological diseases and conditions
WO2021180731A1 (en) * 2020-03-09 2021-09-16 Société des Produits Nestlé S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of cardiovascular diseases and conditions
EP4117681A1 (en) * 2020-03-09 2023-01-18 Société des Produits Nestlé S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of pancreatic diseases and conditions
US20230095103A1 (en) * 2020-03-09 2023-03-30 Societe Des Produits Nestle S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of lung diseases and conditions
CN114561342B (zh) * 2020-11-27 2024-12-20 西安交通大学医学院第一附属医院 Nad信号通路激动剂在体外胚胎培养中的应用
CN115669929A (zh) * 2021-01-15 2023-02-03 江苏恒正合生命科学有限公司 辅助改善记忆的功能性食品其制备方法
US20240245714A1 (en) * 2021-05-05 2024-07-25 Societe Des Produits Nestle S.A. Composition and methods using combination of narh and nr to produce intracellular nicotinamide adenine dinucleotide (nad+)
KR20240020716A (ko) 2021-05-27 2024-02-15 메트로 인터내셔널 바이오테크 엘엘씨 니코틴산 모노뉴클레오타이드 및 이의 에스터의 결정질 고체 및 제조 및 사용 방법
US20230014055A1 (en) * 2021-06-18 2023-01-19 Mitopower Llc Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
JP7111878B1 (ja) 2021-10-27 2022-08-02 旭化成ファーマ株式会社 ニコチンアミドモノヌクレオチドの製造方法
US20240415862A1 (en) * 2021-10-27 2024-12-19 Elysium Health Inc. Methods for treatment of menopausal syndromes
WO2023150072A1 (en) 2022-02-01 2023-08-10 Sinclair David A Compositions and methods for the preservation of plant matter
EP4472993A2 (en) * 2022-02-04 2024-12-11 Elysium Health, Inc. Ribose linkers and conjugates thereof
US12116382B2 (en) 2022-11-28 2024-10-15 Hongene Biotech Corporation Functionalized N-acetylgalactosamine analogs

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003101198A1 (en) 2002-05-30 2003-12-11 Albert Einstein College Of Medicine Of Zeshiva University Improved inhibitors of adp-ribosyl transferases, cyclases, and hydrolases
US20050042736A1 (en) 2003-08-22 2005-02-24 Ka-Yiu San High molar succinate yield bacteria by increasing the intracellular NADH availability
US20050267023A1 (en) 2002-08-09 2005-12-01 Sinclair David A Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
WO2015066382A1 (en) 2013-10-30 2015-05-07 ChromaDex Inc. Nicotinamide riboside compositions for topical use in treating skin conditions
WO2015186114A1 (en) 2014-06-06 2015-12-10 Glaxosmithkline Intellectual Property (No.2) Limited Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005211773B2 (en) 2004-02-10 2009-06-25 Trustees Of Dartmouth College Nicotinamide riboside kinase compositions and methods for using the same
AU2005257883A1 (en) 2004-06-04 2006-01-05 Washington University Methods and compositions for treating neuropathies
EP3369738B1 (en) * 2005-11-18 2020-05-20 Cornell Research Foundation, Inc. Method for making nicotinoyl ribosides and nicotinamide beta-riboside
GB201313465D0 (en) 2013-07-29 2013-09-11 Queens University Of The Belfast Methods of preparing nicotinamide riboside and derivatives thereof
MX390185B (es) * 2015-03-16 2025-03-20 Chromadex Inc Composiciones de acido nicotinico ribosido o de nicotinamida ribosido, derivados reducidos de los mismos, y su uso.
EP3322419B1 (en) 2015-07-15 2025-09-03 Cornell University Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives
EA035664B1 (ru) 2015-08-05 2020-07-23 МЕТРО ИНТЕРНЭШНЛ БАЙОТЕК, ЭлЭлСи Производные никотинамидмононуклеотида и их применение для лечения заболевания или расстройства, связанного с биосинтезом над+
US10857172B2 (en) * 2016-04-14 2020-12-08 Chromadex, Inc. Use of nicotinamide riboside, nicotinic acid riboside, and nicotinamide mononucleotide, reduced nicotinyl compounds, and nicotinoyl compound derivatives in infant formula for healthy development

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003101198A1 (en) 2002-05-30 2003-12-11 Albert Einstein College Of Medicine Of Zeshiva University Improved inhibitors of adp-ribosyl transferases, cyclases, and hydrolases
US20050267023A1 (en) 2002-08-09 2005-12-01 Sinclair David A Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US20050042736A1 (en) 2003-08-22 2005-02-24 Ka-Yiu San High molar succinate yield bacteria by increasing the intracellular NADH availability
WO2015066382A1 (en) 2013-10-30 2015-05-07 ChromaDex Inc. Nicotinamide riboside compositions for topical use in treating skin conditions
WO2015186114A1 (en) 2014-06-06 2015-12-10 Glaxosmithkline Intellectual Property (No.2) Limited Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof

Also Published As

Publication number Publication date
US10183036B2 (en) 2019-01-22
MX393076B (es) 2025-03-24
EP3445359A1 (en) 2019-02-27
JP2019514874A (ja) 2019-06-06
CA3021571C (en) 2023-01-03
WO2017184885A8 (en) 2023-08-24
JP7493007B2 (ja) 2024-05-30
WO2017184885A1 (en) 2017-10-26
US20170304338A1 (en) 2017-10-26
AU2022221384B2 (en) 2023-03-23
ES2948968T3 (es) 2023-09-22
EP3445359C0 (en) 2023-06-07
NZ747693A (en) 2023-07-28
CN109640984A (zh) 2019-04-16
MX2018012849A (es) 2019-08-29
ZA201807736B (en) 2020-05-27
BR112018071573A2 (pt) 2019-02-12
KR20190008246A (ko) 2019-01-23
AU2022221384A1 (en) 2022-09-22
CA3021571A1 (en) 2017-10-26
EP3445359B1 (en) 2023-06-07
JP2021176871A (ja) 2021-11-11
EP3445359A4 (en) 2019-12-25
AU2022221384C1 (en) 2023-08-03
JP2023002685A (ja) 2023-01-10
AU2017254657A1 (en) 2018-11-15
EP3445359B8 (en) 2023-09-06

Similar Documents

Publication Publication Date Title
JP7089480B2 (ja) Ｎａｄ＋を増大させる前駆体としてのニコチン酸リボシド又はニコチンアミドリボシド誘導体、及びその還元誘導体の使用
AU2019214858B2 (en) Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
CA3021022C (en) Use of nicotinamide riboside, nicotinic acid riboside, nicotinamide mononucleotide, and nicotinoyl compound derivatives in infant formula
JP6949002B6 (ja) ニコチンアミドモノヌクレオチド誘導体及びそれらの使用
TWI294875B (en) Phenylindoles for the treatment of hiv
WO2020172629A1 (en) Use of nicotinamide riboside, nicotinic acid riboside, reduced nicotinyl riboside compounds, and nicotinyl riboside compound derivatives in formulations
JP2002523434A (ja) ミトコンドリア疾患の処置のための組成物および方法
JP2022501331A (ja) 少なくとも１つのグリシン又はその誘導体と、少なくとも１つのｎ−アセチルシステイン又はその誘導体と、少なくとも１つのニコチンアミドリボシド又はｎａｄ＋前駆体と、を使用する組成物及び方法
US12186312B2 (en) Sleep improving agent
JP2015028010A (ja) フルオレン−アミド化合物およびその医薬用途
WO2008113072A2 (en) Gpcr enhanced neuroprotection to treat brain injury
HK40004710A (en) Use of nicotinic acid riboside or nicotinamide ribosite derivatives, and reduced derivatives thereof, as nad+increasing precursors
CN107427480A (zh) 用于预防和/或治疗脂肪性肝炎的脂肪酸酰胺
JP7784900B2 (ja) 生理的障害又は状態を治療又は予防するための、トリゴネリンを使用して細胞内ニコチンアミドアデニンジヌクレオチド（ｎａｄ＋）を産生する組成物及び方法
WO2023033166A1 (ja) 心疾患用剤及び心疾患の改善方法
CN118059102A (zh) 一种延缓衰老的药物
JP2020145939A (ja) アレルギー性鼻炎抑制用組成物
HK40001602A (en) Sleep improving agent

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181227

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211012

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220411

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220517

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220610

R150 Certificate of patent or registration of utility model

Ref document number: 7089480

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250